Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 10;13:7921–7932. doi: 10.2147/OTT.S256161

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Zang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

JNK3 modulates EZH2 expression and can serve as a prognostic biomarker. (A) After knockdown of JNK3 for 48 h in two prostate cancer cell lines, EZH2 and p-EZH2 (Thr 311) were detected by Western blot. (B) JNK3 was overexpressed in LNCAP cells, which in turn promoted EZH2 expression. (C) EZH2 positively correlated with JNK3 in prostate cancer clinical samples (n=20). (D) EZH2 protein expression was higher in prostate cancer tumor samples than in adjacent controls (Gleason score 7). (E) TCGA data for EZH2 in prostate cancer samples were analyzed (n =550). (F) Patients with high JNK3 and EZH2 expression had worse outcomes (high expression: 30, low expression: 1445). Each group was compared to the corresponding controls (one-way ANOVA).